Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Kent Osborne

Showing results (31-40 of 158) with videos related to

Pageof 16
Sort By:
Breast Cancer Research and Treatment|January 13, 2009
Low SAFB levels are associated with worse outcome in breast cancer patientsStephanie Hammerich-Hille, Valerie J Bardout, Susan G Hilsenbeck, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2013
Metastasis dormancy in estrogen receptor-positive breast cancerXiang H-F Zhang, Mario Giuliano, Meghana V Trivedi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2004
Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistanceRachel Schiff, Suleiman A Massarweh, Jiang Shou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2005
Insights into the role of progesterone receptors in breast cancerSuzanne A W Fuqua, Yukun Cui, Adrian V Lee, et al.
Nature Reviews. Clinical Oncology|November 30, 2011
Treatment of HER2-positive breast cancer: current status and future perspectivesCarlos L Arteaga, Mark X Sliwkowski, C Kent Osborne, et al.
Journal of the National Cancer Institute|June 17, 2004
Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancerJiang Shou, Suleiman Massarweh, C Kent Osborne, et al.
Cancer Chemotherapy and Pharmacology|November 8, 2005
Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulatorsRachel Schiff, Suleiman A Massarweh, Jiang Shou, et al.
Pharmacotherapy|June 8, 2013
Development of acneiform rash does not predict response to lapatinib treatment in patients with breast cancerJennifer Parma, Anne Pavlick, Rachel Schiff, et al.
Nature Reviews. Clinical Oncology|December 15, 2019
Towards personalized treatment for early stage HER2-positive breast cancerKristina Goutsouliak, Jamunarani Veeraraghavan, Vidyalakshmi Sethunath, et al.
Journal of the National Cancer Institute|September 8, 2005
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistanceGrazia Arpino, Heidi Weiss, Adrian V Lee, et al.
Pageof 16

Showing results (31-40 of 158) with videos related to

Sort By:
Pageof 16
Breast Cancer Research and Treatment|January 13, 2009
Low SAFB levels are associated with worse outcome in breast cancer patientsStephanie Hammerich-Hille, Valerie J Bardout, Susan G Hilsenbeck, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2013
Metastasis dormancy in estrogen receptor-positive breast cancerXiang H-F Zhang, Mario Giuliano, Meghana V Trivedi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2004
Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistanceRachel Schiff, Suleiman A Massarweh, Jiang Shou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2005
Insights into the role of progesterone receptors in breast cancerSuzanne A W Fuqua, Yukun Cui, Adrian V Lee, et al.
Nature Reviews. Clinical Oncology|November 30, 2011
Treatment of HER2-positive breast cancer: current status and future perspectivesCarlos L Arteaga, Mark X Sliwkowski, C Kent Osborne, et al.
Journal of the National Cancer Institute|June 17, 2004
Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancerJiang Shou, Suleiman Massarweh, C Kent Osborne, et al.
Cancer Chemotherapy and Pharmacology|November 8, 2005
Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulatorsRachel Schiff, Suleiman A Massarweh, Jiang Shou, et al.
Pharmacotherapy|June 8, 2013
Development of acneiform rash does not predict response to lapatinib treatment in patients with breast cancerJennifer Parma, Anne Pavlick, Rachel Schiff, et al.
Nature Reviews. Clinical Oncology|December 15, 2019
Towards personalized treatment for early stage HER2-positive breast cancerKristina Goutsouliak, Jamunarani Veeraraghavan, Vidyalakshmi Sethunath, et al.
Journal of the National Cancer Institute|September 8, 2005
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistanceGrazia Arpino, Heidi Weiss, Adrian V Lee, et al.
Pageof 16